COLLPLANT BIOTECHNOLOGIESNEW ($CLGN) posted quarterly earnings results for Q4 2025 on Thursday, March 26th. The company reported earnings of -$0.67 per share, missing estimates of -$0.19 by $0.48. The company also reported revenue of $2,290,000, beating estimates of $1,554,990 by $735,010.
You can see Quiver Quantitative's $CLGN stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
COLLPLANT BIOTECHNOLOGIESNEW Hedge Fund Activity
We have seen 6 institutional investors add shares of COLLPLANT BIOTECHNOLOGIESNEW stock to their portfolio, and 11 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ANSON FUNDS MANAGEMENT LP removed 159,401 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $428,788
- PINNACLE ASSOCIATES LTD added 50,000 shares (+9.9%) to their portfolio in Q4 2025, for an estimated $70,000
- AMH EQUITY LTD added 39,151 shares (+24.3%) to their portfolio in Q3 2025, for an estimated $105,316
- HEIGHTS CAPITAL MANAGEMENT, INC removed 19,258 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $26,961
- VILLERE ST DENIS J & CO LLC added 18,583 shares (+3.2%) to their portfolio in Q4 2025, for an estimated $26,016
- XTX TOPCO LTD added 14,381 shares (+inf%) to their portfolio in Q4 2025, for an estimated $20,133
- VIRTU FINANCIAL LLC added 11,806 shares (+inf%) to their portfolio in Q4 2025, for an estimated $16,528
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
